GH Research PLC Stock

$13.08

0.69% yesterday

Nasdaq, Aug 22, 10:00 pm CET

ISIN

IE000GID8VI0

Symbol

GHRS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

GH Research PLC Stock price

$13.08

-6.17 32.05% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.09 0.69%

ISIN

IE000GID8VI0

Symbol

GHRS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$811.3m

Enterprise Value

$520.4m

Net debt

positive

Cash

$291.5m

Shares outstanding

60.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

2.7

Financial Health

Equity Ratio

95.1%

Return on Equity

-21.8%

ROCE

-17.5%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-52.7m | $-59.1m

EBIT

$-53.0m | $-62.8m

Net Income

$-41.0m | $-57.4m

Free Cash Flow

$-40.4m

EPS

$-0.7

FCF per Share

$-0.7

Short interest

13.3%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

GH Research PLC Stock Analysis

Unlock Scores for Free

??

14 Analysts have issued a GH Research PLC forecast:

13x Buy

93%

More details on Analyst Estimates Including Price Targets

14 Analysts have issued a GH Research PLC forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from GH Research PLC

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	19 19	120% 120% -
- Research and Development Expense	33 33	34% 34% -
EBITDA	-53 -53	56% 56% -
- Depreciation and Amortization	0.32 0.32	33% 33% -
EBIT (Operating Income) EBIT	-53 -53	55% 55% -
Net Profit	-41 -41	50% 50% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

GH Research PLC Stock News

Neutral

GlobeNewsWire

●

16 days ago

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Global pivotal program initiation on track for 2026 Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapy Treatment was well tolerated and no treatment related serious adverse events were reported. There was no evidence of treatment-emergent suic...

Neutral

GlobeNewsWire

●

about one month ago

GH Research Announces Global Pivotal Program Plans and Further Development Updates

DUBLIN, July 23, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today provided updates on its business and key upcoming milestones.

Neutral

GlobeNewsWire

●

2 months ago

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to th...

More GH Research PLC News

Company Profile

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. It develops therapeutic products for the patients who are suffering from Treatment Resistant Depression (TRD). The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Head office	Ireland
CEO	Dr. Valcheva
Employees	50
Founded	2021
Website	www.ghres.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now